Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody Journal Article
| Authors: | Sarlo, K. M.; Dixon, B. N.; Ni, A.; Straus, D. J. |
| Article Title: | Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody |
| Abstract: | Combination of bendamustine (B) and rituximab (R) has been associated with opportunistic infections (OI) in case reports. This retrospective analysis evaluated the incidence, risk factors, and types of infectious complications (IC) in adults with CD20+ non-Hodgkin lymphoma who received ≥2 cycles of B and either R or ofatumumab. Infection data were collected up to 1-year post-B-based treatment. Potential risk factors for IC were assessed using univariate analysis with Fisher's exact test. Four-hundred and sixteen patients were included. Incidence of IC and OI was 20 and 6%, respectively. Viral (n = 19), fungal (n = 1), and Pneumocystis jiroveci pneumonia (n = 5) infections occurred. OI was associated with lack of antimicrobial prophylaxis analysis (p =.048). The incidences of IC and OI with B and anti-CD20 antibody combination at our institution appear lower than those previously reported, possibly due to antimicrobial prophylaxis and G-CSF use. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | rituximab; bendamustine; opportunistic; infectious complications; lymphoma and hodgkin disease |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 61 |
| Issue: | 2 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2020-01-01 |
| Start Page: | 364 |
| End Page: | 369 |
| Language: | English |
| DOI: | 10.1080/10428194.2019.1666378 |
| PUBMED: | 31603363 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 March 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work